Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
Prostate cancer is one of the most common malignant neoplasms in men. Nowadays, the overall mortality rate of this disease continues to increase, including due to the high frequency of primary detection of its widespread and metastatic forms. The effectiveness of hormone therapy of metastatic prostate cancer is limited in time, after which the disease progresses. The use of more aggressive strategies, including chemotherapy, in addition to androgenic deprivation in this category of patients may have some advantages and continues to be discussed. The article presents an overview of the results of clinical studies of docetaxel efficacy in combination with androgen-deprivational therapy in patients with oligometastatic hormone-sensitive prostate cancer. It has been determined that chemotherapy in patients with metastatic hormone-sensitive prostate cancer leads to an increase in the overall survival rate. The effectiveness of chemotherapy may depend on the amount of metastatic lesion. Although the higher efficacy of such treatment is noted in the case of a large volume of metastatic lesion, currently it is impossible to speak unequivocally about the need of adding docetaxel to the androgendeprivational therapy in patients with oligometastatic hormone-sensitive prostate cancer due to the limited statistical power of the presented data and heterogeneity of patients due to the lack of clearly defined criteria of oligometastases. Taking into account these circumstances, future clinical studies to assess the effectiveness of chemotherapy in patients with oligometastatic hormone-sensitive prostate cancer and the analysis of their results can help to expand the boundaries of treatment strategies.